-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MET-4 in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MET-4 in Oropharyngeal Cancer Drug Details: MET-4 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Telotristat Ethyl in Neuroendocrine Tumors
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Telotristat Ethyl in Neuroendocrine Tumors Drug Details:Telotristat ethyl (LX1606, LX1032, Xermelo) is a paraneoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KITE-363 in Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KITE-363 in Chronic Lymphocytic Leukemia (CLL) Drug Details: KITE-363 is under development for the...
-
Product Insights
![]()
Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neuroendocrine Tumors Pipeline Drugs Market Report Overview Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. The Neuroendocrine Tumors pipeline drugs market research report provides comprehensive information on the therapeutics under development for...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – telotristat ethyl
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry telotristat ethyl Drug Details Telotristat ethyl (LX1606, LX1032, Xermelo) is a paraneoplastic agent. It...
-
Sector Analysis
![]()
Supportive Care in Cancer – Comprehensive Overview, Pipeline Products, Research and Development Strategies and Unmet Needs
Supportive care in cancer is an evolving discipline of medicine that is critical for holistic management of patients with cancer. With significant advancements being made in treatment of cancer particularly through development of immuno-oncology (IO) and targeted therapies, it is of equal significance to focus on supportive care in cancer so as to ensure that patients are able to complete the treatment cycle for the primary cancer as well as to enhance their quality of life. The report leverages on...
-
Sector Analysis
![]()
Prostate Cancer – Global Drug Forecast and Market Analysis to 2028
The prostate cancer market in the 8 major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) is expected to experience a moderate growth between 2018 and 2018. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naïve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide). Until recently, the hormone...
-
Sector Analysis
![]()
Digital Landscape: Breast Cancer
The Digital Landscape Breast Cancer report analyzes digital activities undertaken by pharma in support of therapies for breast cancer.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.